Contrasting Lunai Bioworks (NASDAQ:LNAI) & AngioSoma (OTCMKTS:SOAN)

AngioSoma (OTCMKTS:SOAN) and Lunai Bioworks (NASDAQ:LNAI) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their risk, valuation, profitability, analyst recommendations, earnings, institutional ownership and dividends.

Earnings and Valuation

This table compares AngioSoma and Lunai Bioworks”s revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
AngioSoma	N/A	N/A	-$540,000.00	N/A	N/A
Lunai Bioworks	N/A	N/A	-$178.01 million	($0.07)	-13.71

Profitability

This table compares AngioSoma and Lunai Bioworks’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
AngioSoma	N/A	N/A	-1,245.34%
Lunai Bioworks	N/A	-378.07%	-210.59%

Volatility and Risk

AngioSoma has a beta of -0.46, indicating that its stock price is 146% less volatile than the S&P 500. Comparatively, Lunai Bioworks has a beta of 0.4, indicating that its stock price is 60% less volatile than the S&P 500.

Institutional and Insider Ownership

0.0% of AngioSoma shares are owned by institutional investors. Comparatively, 71.4% of Lunai Bioworks shares are owned by institutional investors. 0.5% of Lunai Bioworks shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Analyst Ratings

This is a summary of recent ratings and recommmendations for AngioSoma and Lunai Bioworks, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
AngioSoma	0	0	0	0	0.00
Lunai Bioworks	1	0	0	0	1.00

Given AngioSoma’s higher probable upside, research analysts clearly believe AngioSoma is more favorable than Lunai Bioworks.

Summary

Lunai Bioworks beats AngioSoma on 5 of the 8 factors compared between the two stocks.

About AngioSoma

AngioSoma, Inc., a wellness company, engages in the development and commercialization of dietary supplements to the medical, wellness, and adult-use markets. The company was founded in 2016 and is based in Houston, Texas.

About Lunai Bioworks

Enochian Biosciences, Inc., a pre-clinical stage biotechnology company, engages in the research and development of pharmaceutical and biological products for the human treatment of human immunodeficiency virus (HIV), hepatitis B virus (HBV), influenza and coronavirus infections, and cancer. The company’s lead candidate includes ENOB-HV-01 for autologous HIV curative treatment; ENOB-HV-11, a preventative HIV vaccine; ENOB-HV-12, a therapeutic HIV vaccine; and ENOB-HB-01, a coopting HBV polymerase. Its pipeline development products comprise ENOB-DC-11 off the shelf DC vaccine for multiple solid tumors; and ENOB-DC-21, a non-specific vaccine for intraturmoral injection. Enochian Biosciences, Inc. has strategic partnerships with The Scripps Institute, Fred Hutchinson Cancer Research Center, the Texas Biomedical Research Institute, the University of California, Los Angeles, and The Hepatitis B Foundation and Baruch S. Blumberg Institute. The company was incorporated in 2017 and is headquartered in Los Angeles, California.